ClinicalTrials.gg
RecruitingNCT06930885EPOCAUpdated Jan 22, 2026

Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease

A Phase 3 interventional study of Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) and Colchicine 0.5 mg in Atherothrombotic Diseases and Atherosclerotic Cardiovascular Disease (ASCVD), sponsored by Hospital do Coracao. Recruiting at 13 sites in Brazil. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Hospital do Coracao · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,713
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing colchicine in Atherosclerosis — 7 open to participants now, 9 under way, 3 of them phase 3. Colchicine · Atherosclerosis.

Planned enrollment
Largest of 17
7,713 · median 115
Started
2025
with 1 other
Phase 3
5 of 17
3 open now
Registered
13th of 17
by date
Lead sponsor
1 of 17
Hospital do Coracao

Among the 17 studies testing colchicine in Atherosclerosis, this one has the largest planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 13th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

7 of the 17 studies testing colchicine in Atherosclerosis are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing colchicine in Atherosclerosis, or all of them as a file.
02

Study summary

The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.

Read the detailed description

Cardiovascular disease is the leading cause of morbidity and mortality worldwide and in Brazil. Additionally, cardiovascular risk factors are highly prevalent conditions which are, frequently, present in association. Despite the last therapeutic advances, rates of adequate control of these conditions are still low. One proposed strategy to increase such control and decrease cardiovascular risk is the use of fixed-dose combinations of different pharmacological classes, to be taken on single daily dose - a polypill. This strategy has already been studied in other parts of the world, especially in patients with established or at risk for coronary heart disease (CHD).

Furthermore, there has been a need to explore other therapeutic targets beyond traditional risk factors that could impact the process of atherosclerosis. Among the various options evaluated, colchicine has emerged as a viable alternative, given its clinical use experience, mechanism of action, and the results showing a reduction in inflammatory biomarkers as well as clinical outcomes in individuals with different manifestations of coronary artery disease. However, it is important to highlight some key points regarding the available studies evaluating both the treatment strategy based on a polypill and the use of colchicine in the context of atherosclerotic cardiovascular disease (ASCVD).

The studies supporting both approaches were primarily conducted with participants with coronary artery disease from centers in Europe, the U.S., Iran, Oceania, and India, and there is a lack of robust evidence regarding these therapeutic strategies in other countries with a diverse population like Brazil, as well as in individuals with other manifestations of ASCVD (including peripheral arterial disease and cerebrovascular disease).

Given high prevalence of atherosclerotic cardiovascular disease and its traditional risk factors, low control rates, high levels of poor adherence and therapeutic inertia, and the specific realities of the population and healthcare system, evaluating the efficacy of a polypill strategy (fixed-dose an antihypertensive, aspirin, and high-potency statin) with a single daily dose, along with colchicine, in preventing cardiovascular events could contribute to improving cardiovascular care.

03

Conditions studied

  • Atherothrombotic Diseases
  • Atherosclerotic Cardiovascular Disease (ASCVD)

Browse trials for

Keywords

  • Atherothrombotic diseases
  • Atherosclerotic cardiovascular disease
  • Polypill
  • Colchicine
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged ≥ 45 years AND
  • Signature of the Form (ICF) AND at least one of the following criteria:
  • Previous atherothrombotic cardiovascular event (acute coronary syndrome, ischemic stroke, high-risk transient ischemic stroke, acute limb ischemia/arterial occlusion, or non-traumatic limb amputation) AND/OR
  • Previous arterial revascularization (percutaneous, surgical, and/or hybrid) OR
  • Diagnosis of significant atherosclerotic disease with ≥ 50% obstruction in any arterial territory (coronary, cerebrovascular, or peripheral), in the absence of a prior cardiovascular event or arterial revascularization.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women;
  • Women of childbearing age who do not use any form of ;
  • Known history of chronic kidney disease, stage ≥ 4 (estimated ≤ 30 mL/min, if available);
  • Known history of cirrhosis or severe liver disease (e.g., transaminase levels > 3 times the , if available);
  • Known history of inflammatory muscle disease (e.g., dermatomyositis or polymyositis) or creatine phosphokinase (CPK) levels > 3 times the upper limit of normal, if available);
  • Known history of moderate or severe valvular heart disease with anticipated need for valvular intervention within the next 12 months;
  • Planned arterial revascularization (inclusion is possible 30 days after completion of all planned procedures);
  • ≤40% (with the exception of patients with documented intolerance to ACE inhibitors and/or sacubitril/valsartan, who remain eligible for study enrollment);
  • Heart failure with functional class ≥ III according to the (NYHA), regardless of left ventricular ejection fraction;
  • Blood pressure \< 120/80 mmHg in the absence of antihypertensive therapy;
  • ≤ 12 months;
  • Acute arterial event (acute coronary syndrome, non-cardioembolic ischemic stroke, acute limb ischemia) in the past 30 days;
  • Substance abuse/alcoholism;
  • Psychiatric and/or neurodegenerative disorder limiting self-care capacity;
  • Concurrent participation in another randomized clinical trial;
  • to any component of the polypill;
  • Current or planned use of oral anticoagulant therapy within the next 12 months (except rivaroxaban 2.5 mg twice daily for patients with peripheral artery disease);
  • High risk of bleeding (e.g., but not limited to: blood dyscrasias, hemophilia, previous gastrointestinal or central nervous system bleeding);
  • Contraindication to colchicine;
  • Current use of colchicine.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7,713 participants (estimated)

Study arms

  • Experimental
    Group 1

    Cardiovascular Polypill + Colchicine 0.5 mg once daily

    Drug: Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) · Drug: Colchicine 0.5 mg

  • Experimental
    Group 2

    Cardiovascular Polypill + Colchicine placebo 0.5 mg once daily

    Drug: Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) · Drug: Colchicine-placebo 0.5 mg

  • Experimental
    Group 3

    Usual care + Colchicine 0.5 mg once daily

    Drug: Colchicine 0.5 mg · Drug: Usual Care Group

  • Experimental
    Group 4

    Usual care + Colchicine placebo 0.5 mg once daily

    Drug: Usual Care Group · Drug: Colchicine-placebo 0.5 mg

Interventions

  • DrugCardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)

    Cardiovascular Polypill contains Valsartan, Atorvastatin, Aspirin 1. Valsartan 160 mg + Atorvastatin 40 mg + Aspirin 100 mg or 2. Valsartan 160 mg + Atorvastatin 80 mg + Aspirin 100 mg or 3. Valsartan 320 mg + Atorvastatin 40 mg + Aspirin 100 mg or 4. Valsartan 320 mg + Atorvastatin 80 mg + Aspirin100 mg or 5. Valsartan 80 mg + Atorvastatin 40 mg + Aspirin 100 mg or 6. Valsartan 80 mg + Atorvastatin 80 mg + Aspirin 100 mg or 7. Valsartan 80 mg + Atorvastatin 20 mg + Aspirin 100 mg\* or 8. Valsartan 160 mg + Atorvastatin 20 mg + Aspirin 100 mg\* or 9. Valsartan 320 mg + Atorvastatin 20 mg + Aspirin 100 mg\* * The use of these formulations of the cardiovascular polypill will be restricted to cases of Statin-Related Muscle Symptoms (SRMS)

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine 0.5 mg once daily

  • DrugUsual Care Group

    Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the guidelines. Drugs and doses will be left at the discretion of the treating physicians.

  • DrugColchicine-placebo 0.5 mg

    Matching Colchicine-placebo 0.5 mg once daily

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint: Major adverse cardiovascular and limb events (MACLE)

    Time to cardiovascular death, non-fatal type 1 myocardial infarction, non-fatal ischemic stroke, urgent arterial revascularization, and non-traumatic major lower limb amputation

    Time frame: Through study completion, an estimated average of 3 years

Secondary outcomes

  1. Key secondary endpoint: Major adverse cardiovascular events (MACE)

    Time to cardiovascular mortality, non-fatal type 1 myocardial infarction, and non-fatal ischemic stroke.

    Time frame: Through study completion, an estimated average of 3 years

  2. Cardiovascular death

    Time to cardiovascular death

    Time frame: Through study completion, an estimated average of 3 years

  3. Non-fatal type 1 myocardial infarction

    Time to non-fatal type 1 myocardial infarction

    Time frame: Through study completion, an estimated average of 3 years

  4. Non-fatal ischemic stroke

    Time to non-fatal ischemic stroke

    Time frame: Through study completion, an estimated average of 3 years

Other outcomes

  1. Change in Treatment Adherence

    It will be assessed through the 9-item adapted Hill-Bone Medication Adherence Scale. The adapted 9-item Hill-Bone Medication Adherence Scale consists of 9 questions, each rated on a 4-point Likert scale ('all of the time', 'most of the time', 'some of the time', 'none of the time'). Item scores range from 1 to 4, yielding a total score between 9 and 36. Higher scores reflect poorer adherence, whereas lower scores reflect better adherence.

    Time frame: Through study completion, an estimated average of 3 years

  2. Change in Systolic and Diastolic Blood Pressure (SBP and DBP)

    Systolic and diastolic blood pressure will be assessed and summarized at each timepoint.

    Time frame: Through study completion, an estimated average of 3 years

  3. Change in serum LDL-c concentrations

    Non-fasting blood analysis will be collected and LDL cholesterol level evaluated at each timepoint.

    Time frame: Through study completion, an estimated average of 3 years

  4. Change in serum concentrations of high-sensitivity C-reactive protein (hs-CRP)

    High-sensitivity C-reactive protein (hs-CRP) will be colllected and evaluated at each timepoint

    Time frame: Through study completion, an estimated average of 3 years

  5. Proportion of individuals with controlled blood pressure

    Systolic and diastolic blood pressure will be collected and the proportions of patients with controled blood pressure will be summarized at each timepoint

    Time frame: Through study completion, an estimated average of 3 years

  6. Proportion of individuals with LDL-c levels at target

    Non-fasting blood analysis will be collected and the proportion of individuals with LDL-c levels at target will be evaluated at each timepoint

    Time frame: Through study completion, an estimated average of 3 years

  7. Change in Quality of Life

    The European Quality of Life - 5 Dimensions 5 Levels (EQ-5D-5L) Questionnaire will be administered at each timepoint to evaluate changes in quality of life. The EQ-5D-5L includes a descriptive system and a visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each with five levels of severity. Responses generate a five-digit health profile. The EQ VAS captures the participant's self-rated health on a visual scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine").

    Time frame: Through study completion, an estimated average of 3 years

  8. Safety endpoint: All-cause death

    Time to all-cause death

    Time frame: Through study completion, an estimated average of 3 years

  9. Safety endpoint: Bleeding

    It will be assessed according to the definitions of the Bleeding Academic Research Consortium.

    Time frame: Through study completion, an estimated average of 3 years

  10. Safety endpoint: Hospitalization for sepsis

    Time to hospitalization for sepsis

    Time frame: Through study completion, an estimated average of 3 years

  11. Safety endpoint: new diagnonis of cancer

    Time of ocurrence of new diagnosis of cancer

    Time frame: Through study completion, an estimated average of 3 years

07

Study locations

13 of 13 sites recruiting
  • Centro de Pesquisas Clínicas Dr. Marco Mota
    Maceió, Alabama 57051160, Brazil
    Recruiting
  • Secretária da Saúde do Estado do Ceará - Hospital de Messejana Dr. Carlos Alberto Studart Gomes
    Messejana, Ceará, Brazil
    Recruiting
  • Empresa Brasileira de Serviços Hospitalares - EBSERCH - Hospital de Ensino Dr. Washington Antônio de Barros- HU-UNIVASF
    Petrolina, Pernambuco, Brazil
    Recruiting
  • Centro de Pesquisa Cardiolima
    Teresina, Piauí, Brazil
    Recruiting
  • Fundação Técnico Educacional Souza Marques
    Rio de Janeiro, Rio de Janeiro 22.793-140, Brazil
    Recruiting
  • Fundação Universitária de Cardiologia - ICFUC
    Porto Alegre, Rio Grande do Sul, Brazil
    Recruiting
  • Instituto de Pesquisa e Ensino em Saúde - IPES
    Porto Velho, Rondônia, Brazil
    Recruiting
  • CMEP - Centro Multidisciplinar de Ensino especializado e Pesquisa
    Joinville, Santa Catarina, Brazil
    Recruiting
  • Hospital Universitário São Francisco na Providência de Deus
    Bragança Paulista, São Paulo, Brazil
    Recruiting
  • Fundação Faculdade Regional de Medicina São José do Rio Preto
    São José do Rio Preto, São Paulo 15.090-000, Brazil
    Recruiting
  • CIPES - Centro Internacional de Pesquisa Clínica
    São José dos Campos, São Paulo, Brazil
    Recruiting
  • Hcor
    São Paulo, São Paulo 04004-030, Brazil
    Recruiting
  • Centro de Pesquisa Cetrus
    São Paulo, São Paulo, Brazil
    Recruiting
08

References and documents

Publications

  • Tramujas L, Nogueira A, Felix N, Maia I, de Barros E Silva PGM, Cavalcanti AB, Abizaid A. Trends in colchicine use across the spectrum of coronary artery disease. Vascul Pharmacol. 2025 Jun;159:107502. doi: 10.1016/j.vph.2025.107502. Epub 2025 May 13. No abstract available. PubMed 40373935 ↗
  • de Barros E Silva PGM, do Nascimento CT, Pedrosa RP, Nakazone MA, do Nascimento MU, de Araujo Melo L, Junior OLS, Zimmermann SL, de Melo RMV, Bergo RR, Precoma DB, Tramujas L, Lima EG, Dantas JMM, do Amaral Baruzzi AC, Flumignan RLG, de Oliveira Paiva MSM, Gowdak LHW, de Carvalho PN, de Figueiredo Neto JA, Silvestre OM, Fioranelli A, Vieira RD', Horak ACP, Miyada DHK, Kojima FCS, de Oliveira JS, de Oliveira Silva L, Pavanello R, Ramacciotti E, Lopes RD; NEAT Investigators. Primary results of the brazilian registry of atherothrombotic disease (NEAT). Sci Rep. 2024 Feb 20;14(1):4222. doi: 10.1038/s41598-024-54516-9. PubMed 38378735 ↗
  • de Abreu-Silva EO, Siepmann M, Siepmann T. Polypills in the Management of Cardiovascular Risk-A Perspective. J Clin Med. 2024 Sep 16;13(18):5487. doi: 10.3390/jcm13185487. PubMed 39336974 ↗
  • Tramujas L, Nogueira A, Felix N, de Barros E Silva PGM, Abizaid A, Cavalcanti AB. Association of colchicine use with cardiovascular and limb events in peripheral artery disease: Insights from a retrospective cohort study. Atherosclerosis. 2024 Nov;398:118563. doi: 10.1016/j.atherosclerosis.2024.118563. Epub 2024 Aug 9. PubMed 39299823 ↗

Individual participant data

Plan to share: Yes — Our data dissemination plan will follow the rules of the Hcor research institute

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 1 year after the publication

Access criteria: Submission of a statistical analysis plan for the purposed analyses. Compliance with Brazilian. data privacy law.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2031, 71 months after the start.

Of 54 phase 3 interventional studies under Atherosclerosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 16, 2025
StartActual
Jun 12, 2025
Primary completionEst.
May 2031
CompletionEst.
May 2031
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06930885
Lead sponsor
Hospital do Coracao
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
Jun 12, 2025
Primary completion
May 2031 (estimated)
Completion
May 2031 (estimated)
Last update
Jan 22, 2026

Study contacts

Pedro Gabriel Melo de Barros e Silva, P.h.D
study chair · Hcor Research Institute
Lucas tramujas, M.D
principal investigator · Hcor Research Institute
Erlon Oliveira de Abreu-Silva, M.D
principal investigator · Hcor Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion